• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Evonik invests in Allay Therapeutics to reduce need for opioids

December 13, 2022 By Sean Whooley

Allay Therapeutics EvonikEvonik announced today that it invested in Allay Therapeutics and its implant for treating pain after knee surgery.

Inserted directly into the knee, the Allay implant may relieve pain for up to three weeks, according to a news release. Previous solutions worked for a maximum of three days, the company said.

The technology helps promote the recovery process and potentially reduce or eliminate the administration of common opioid painkillers. Those include morphine or oxycodone. Using biodegradable polymers from Evonik, the new type of pain therapy could ensure the delivery of active ingredients over a longer period.

“Our products may provide patients with pain relief exactly when they need it most – for weeks instead of days. This would significantly improve and accelerate the recovery process,” said Adam Gridley, CEO of Allay Therapeutics.

About the implants

Allay designed its implants at about the size of a coin for placement around the implanted knee joint at the end of surgery. They consist of a proven local non-opioid anesthetic and polymers from Evonik. The anesthetic blocks the transmission of pain signals to the spinal cord. This stops the pain impulse before it reaches the brain.

Evonik said Allay succeeded in extending the delivery of up to three weeks through a novel active ingredient polymer architecture. The polymers ensure the delivery in a controlled fashion over a long period as the implants gradually dissolve before the body breaks them down.

“We are pleased to be able to support our partner Allay in developing this promising innovation. It can fundamentally change pain management and take away patients’ fear of surgery,” said Paul Spencer, head of the drug delivery & products line in Evonik’s health care business. The Evonik health care business supplies the biodegradable polymer processed in the Allay implant.

According to the company, the technology could be adapted for other orthopedic and soft tissue surgeries.

“Allay’s pain products can become a game-changer in postoperative pain management,” said Bernhard Mohr, head of Evonik Venture Capital. “They may reduce the problems that opioids bring, such as dependence, further hospitalization, lengthy rehabilitation, and overall costs to the healthcare system.”

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Orthopedics Tagged With: Allay Therapeutics, Evonik

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS